PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer

Huiyu Xu, Yong Han, Jiaying Lou, Hongxian Zhang, Yue Zhao, B. Györffy, Rong Li

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To explore the key genes associated with both PCOS and breast cancer, we overlapped the synchronously differently expressed genes in two obese insulinresistant GEO datasets in muscle tissue and genes exert essential roles in breast cancer prognosis together base on the following reasons: (1) Androgens excess is believed to contribute to the onset of both PCOS and breast cancer. (2) PCOS is usually complicated with metabolic symptoms, such as obesity and insulin-resistance. (3) Muscle is the main place where energy metabolism and material metabolism take place. Consequently, 53 genes were found, functionally enriched in pathways such as pyruvate metabolism, muscle system process and development of primary male sexual characteristics etc. We further lay our eyes on genes correlated with male sexual characteristics, which may be involved in the onset of both PCOS and breast cancer. Three genes were indicated to be associated with this process, including hydroxysteroid (17-beta) dehydrogenase 4/HSD17B4, platelet-derived growth factor receptor, alpha polypeptide/PDGFRA and high-mobility group box 2/HMGB2. Gene-drug interaction network about the three genes were then constructed. Drugs or chemicals that contribute to correcting the disorder of lipid metabolism were detected to restore the abnormal expression of the three genes in PCOS, such as simvastatin, bezafibrate, fenofibrate et al, which provide further choices for managing patients with PCOS.

Original languageEnglish
Pages (from-to)69520-69526
Number of pages7
JournalOncotarget
Volume8
Issue number41
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

HMGB2 Protein
Polycystic Ovary Syndrome
Ovarian Neoplasms
Breast Neoplasms
Genes
Peroxisomal Multifunctional Protein-2
Muscles
Therapeutics
Lipid Metabolism Disorders
Bezafibrate
Platelet-Derived Growth Factor alpha Receptor
Fenofibrate
Simvastatin
Essential Genes
Pyruvic Acid
Drug Interactions
Energy Metabolism
Androgens
Insulin Resistance
Obesity

Keywords

  • Breast cancer
  • Insulin-resistant
  • Muscle
  • Obese
  • PCOS

ASJC Scopus subject areas

  • Oncology

Cite this

PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. / Xu, Huiyu; Han, Yong; Lou, Jiaying; Zhang, Hongxian; Zhao, Yue; Györffy, B.; Li, Rong.

In: Oncotarget, Vol. 8, No. 41, 01.01.2017, p. 69520-69526.

Research output: Contribution to journalArticle

Xu, Huiyu ; Han, Yong ; Lou, Jiaying ; Zhang, Hongxian ; Zhao, Yue ; Györffy, B. ; Li, Rong. / PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. In: Oncotarget. 2017 ; Vol. 8, No. 41. pp. 69520-69526.
@article{68081782de82433dba54d9f536f92526,
title = "PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer",
abstract = "To explore the key genes associated with both PCOS and breast cancer, we overlapped the synchronously differently expressed genes in two obese insulinresistant GEO datasets in muscle tissue and genes exert essential roles in breast cancer prognosis together base on the following reasons: (1) Androgens excess is believed to contribute to the onset of both PCOS and breast cancer. (2) PCOS is usually complicated with metabolic symptoms, such as obesity and insulin-resistance. (3) Muscle is the main place where energy metabolism and material metabolism take place. Consequently, 53 genes were found, functionally enriched in pathways such as pyruvate metabolism, muscle system process and development of primary male sexual characteristics etc. We further lay our eyes on genes correlated with male sexual characteristics, which may be involved in the onset of both PCOS and breast cancer. Three genes were indicated to be associated with this process, including hydroxysteroid (17-beta) dehydrogenase 4/HSD17B4, platelet-derived growth factor receptor, alpha polypeptide/PDGFRA and high-mobility group box 2/HMGB2. Gene-drug interaction network about the three genes were then constructed. Drugs or chemicals that contribute to correcting the disorder of lipid metabolism were detected to restore the abnormal expression of the three genes in PCOS, such as simvastatin, bezafibrate, fenofibrate et al, which provide further choices for managing patients with PCOS.",
keywords = "Breast cancer, Insulin-resistant, Muscle, Obese, PCOS",
author = "Huiyu Xu and Yong Han and Jiaying Lou and Hongxian Zhang and Yue Zhao and B. Gy{\"o}rffy and Rong Li",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.17846",
language = "English",
volume = "8",
pages = "69520--69526",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "41",

}

TY - JOUR

T1 - PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer

AU - Xu, Huiyu

AU - Han, Yong

AU - Lou, Jiaying

AU - Zhang, Hongxian

AU - Zhao, Yue

AU - Györffy, B.

AU - Li, Rong

PY - 2017/1/1

Y1 - 2017/1/1

N2 - To explore the key genes associated with both PCOS and breast cancer, we overlapped the synchronously differently expressed genes in two obese insulinresistant GEO datasets in muscle tissue and genes exert essential roles in breast cancer prognosis together base on the following reasons: (1) Androgens excess is believed to contribute to the onset of both PCOS and breast cancer. (2) PCOS is usually complicated with metabolic symptoms, such as obesity and insulin-resistance. (3) Muscle is the main place where energy metabolism and material metabolism take place. Consequently, 53 genes were found, functionally enriched in pathways such as pyruvate metabolism, muscle system process and development of primary male sexual characteristics etc. We further lay our eyes on genes correlated with male sexual characteristics, which may be involved in the onset of both PCOS and breast cancer. Three genes were indicated to be associated with this process, including hydroxysteroid (17-beta) dehydrogenase 4/HSD17B4, platelet-derived growth factor receptor, alpha polypeptide/PDGFRA and high-mobility group box 2/HMGB2. Gene-drug interaction network about the three genes were then constructed. Drugs or chemicals that contribute to correcting the disorder of lipid metabolism were detected to restore the abnormal expression of the three genes in PCOS, such as simvastatin, bezafibrate, fenofibrate et al, which provide further choices for managing patients with PCOS.

AB - To explore the key genes associated with both PCOS and breast cancer, we overlapped the synchronously differently expressed genes in two obese insulinresistant GEO datasets in muscle tissue and genes exert essential roles in breast cancer prognosis together base on the following reasons: (1) Androgens excess is believed to contribute to the onset of both PCOS and breast cancer. (2) PCOS is usually complicated with metabolic symptoms, such as obesity and insulin-resistance. (3) Muscle is the main place where energy metabolism and material metabolism take place. Consequently, 53 genes were found, functionally enriched in pathways such as pyruvate metabolism, muscle system process and development of primary male sexual characteristics etc. We further lay our eyes on genes correlated with male sexual characteristics, which may be involved in the onset of both PCOS and breast cancer. Three genes were indicated to be associated with this process, including hydroxysteroid (17-beta) dehydrogenase 4/HSD17B4, platelet-derived growth factor receptor, alpha polypeptide/PDGFRA and high-mobility group box 2/HMGB2. Gene-drug interaction network about the three genes were then constructed. Drugs or chemicals that contribute to correcting the disorder of lipid metabolism were detected to restore the abnormal expression of the three genes in PCOS, such as simvastatin, bezafibrate, fenofibrate et al, which provide further choices for managing patients with PCOS.

KW - Breast cancer

KW - Insulin-resistant

KW - Muscle

KW - Obese

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=85030263065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030263065&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17846

DO - 10.18632/oncotarget.17846

M3 - Article

AN - SCOPUS:85030263065

VL - 8

SP - 69520

EP - 69526

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -